Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 2


Patients with metastatic castration-resistant prostate cancer (mCRPC) frequently receive docetaxel after they develop resistance to abiraterone or enz…

  • 123456 Profile photo of Madelyn

    Be on the lookout for the phase 3 trial of pembro/docetaxel. Here are the phase 2 results of the single arm study.